Surfing NASH extends its preview coverage of the upcoming EASL Congress with a three-part episode. This conversation comes from our final segment with Ian Rowe, Jörn Schattenberg and Roger Green.
Jörn leads with thoughts around the Abstract session – NAFLD: Clinical Aspects. The session will touch on aspects that are, as Jörn puts it, “very close to what we’re thinking today when we see patients.” He notes that topics covered around tools available now for treating and management will be of interest and utility for those seeing NASH patients. The group goes on to unpack this session before exploring presentations around pathology and developing understanding of disease staging, lean NAFLD, the role of miRNA, mitigating screening challenges and more. Jörn expresses excitement around his presentation of a poster as part of a cluster of NAIL-NIT data to emerge.
The world’s largest liver meeting takes place 21-24 June in Vienna with an international faculty of experts from over 200 institutions. The diverse program will feature 2500 abstracts and be a uniquely momentous occasion for developing multidisciplinary approaches aimed at putting a major dent in Fatty Liver disease. Stay tuned for more coverage and if you have any question or interests around the event, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Today’s episode is sponsored by HistoIndex, the first global company to provide stain-free, fully automated imaging solutions for visualizing and quantifying morphological and architectural features of fibrosis. HistoIndex couples breakthrough biophotonic technology with an AI-powered digital pathology system to provide consistent, high-throughput imaging in liver disease and cancer. The platform benefits clinical research and speeds development of drugs and diagnostics. For more information, visit www.histoindex.com.
Stay Safe and Surf On!
